LoQus23 Exits Stealth Mode to Target Huntington's and Other Triplet Repeat Diseases

Dementia Discovery Fund spinout LoQus23 Therapeutics announced the closing of a $15.4M seed fund, which the Cambridge-based company plans to use to develop drug candidates to target Huntington's disease and other triplet repeat disorders.

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,London ,City Of ,Caroline Benn ,Christian Jung ,Ruth Mckernan ,David Reynolds ,Kings College London ,Astex Pharmaceuticals ,Harvard Medical School ,Dementia Discovery Fund ,Pfizer ,Uk Dementia Discovery Fund ,Novartis Venture Fund ,Lundbeck ,Discovery Fund ,Merck Sharp ,Dementia Discovery ,Adrestia Therapeutics ,